Top

Published in:

01-10-2016 | Original Article

The anti-oncogenic influence of ellagic acid on colon cancer cells in leptin-enriched microenvironment

Authors: Amany I. Yousef, Omar S. El-Masry, Eman H. Yassin

Published in: Tumor Biology | Issue 10/2016

Abstract

Ellagic acid (EA) has been proposed as a promising candidate for therapeutic use in colon cancer. Investigation of the effectiveness of EA in a leptin-enriched model might have been given a little interest. Here in, we investigated the anti-tumor effect of EA in the presence of leptin to reflect on therapeutic use of EA in obesity-linked colon cancer. Proven effective in leptin-enriched microenvironment, EA inhibited cell proliferation of HCT-116 and CaCo-2 cell lines, modulated cell cycle, translocated Bax to the mitochondrial fraction of cells, activated caspase-8, and reduced PCNA expression. The current study findings cast a beam of light on the potential therapeutic use of EA in obesity-related colon carcinogenesis.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. doi:10.1016/j.ejca.2012.12.027.CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.CrossRefPubMed

Alexander J, Rodríguez CM, Paz-Filho G. Leptin as a risk factor for the development of colorectal cancer. Transl Gastrointest Cancer. 2013;2(4):211–22.

Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56. doi:10.1210/jc.2004-0395.CrossRefPubMed

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/S0140-6736(08)60269-X.CrossRefPubMed

Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62(6):933–47. doi:10.1136/gutjnl-2013-304701.CrossRefPubMed

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34. doi:10.1056/NEJMoa1305275.CrossRefPubMed

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62. doi:10.1200/JCO.2011.38.0915.CrossRefPubMed

Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer. Mutagenesis. 2012;27(2):211–8. doi:10.1093/mutage/ger067.CrossRefPubMed

10.

Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci. Landmark Ed2011;16:1634–50.CrossRef

11.

Drew JE. Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proc Nutr Soc. 2012;71(1):175–80. doi:10.1017/S0029665111003259.CrossRefPubMed

12.

Paz-Filho G, Mastronardi C, Franco CB, Wang KB, Wong ML, Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metabol. 2012;56(9):597–607.CrossRefPubMed

13.

Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013;62(1):81–5. doi:10.1016/j.cyto.2013.02.012.CrossRefPubMed

14.

Chibaudel B, Tournigand C, Andre T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4(2):75–89. doi:10.1177/1758834011431592.CrossRefPubMedPubMedCentral

15.

Zhang HM, Zhao L, Li H, Xu H, Chen WW, Tao L. Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med. 2014;11(2):92–100. doi:10.7497/j.issn.2095-3941.2014.02.004.PubMedPubMedCentral

16.

Gonzalez-Sarrias A, Nunez-Sanchez MA, Tome-Carneiro J, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Comprehensive characterization of the effects of ellagic acid and urolithins on colorectal cancer and key-associated molecular hallmarks: MicroRNA cell specific induction of CDKN1A (p21) as a common mechanism involved. Mol Nutr Food Res. 2016;60(4):701–16. doi:10.1002/mnfr.201500780.CrossRefPubMed

17.

Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58. doi:10.1016/S1470-2045(12)70073-6.CrossRefPubMed

18.

Umesalma S, Sudhandiran G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur J Pharmacol. 2011;660(2–3):249–58. doi:10.1016/j.ejphar.2011.03.036.CrossRefPubMed

19.

Ramirez de Molina A, Vargas T, Molina S, Sanchez J, Martinez-Romero J, Gonzalez-Vallinas M, et al. The ellagic acid derivative 4,4′-di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16. J Pharmacol Exp Ther. 2015;353(2):433–44. doi:10.1124/jpet.114.221796.CrossRefPubMed

20.

Larrosa M, Tomas-Barberan FA, Espin JC. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem. 2006;17(9):611–25. doi:10.1016/j.jnutbio.2005.09.004.CrossRefPubMed

21.

Lei F, Zhang XN, Wang W, Xing DM, Xie WD, Su H, et al. Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. Int J Obes. 2007;31(6):1023–9. doi:10.1038/sj.ijo.0803502.CrossRef

22.

Wang L, Li L, Ran X, Long M, Zhang M, Tao Y, et al. Ellagic acid reduces adipogenesis through inhibition of differentiation-prevention of the induction of Rb phosphorylation in 3 T3-L1 adipocytes. Evid Based Complement Alternat Med. 2013;2013:287534. doi:10.1155/2013/287534.PubMedPubMedCentral

23.

Marin M, Maria Giner R, Rios JL, Recio MC. Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J Ethnopharmacol. 2013;150(3):925–34. doi:10.1016/j.jep.2013.09.030.CrossRefPubMed

24.

Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem. 2006;54(3):980–5. doi:10.1021/jf052005r.CrossRefPubMed

25.

Vanella L, Di Giacomo C, Acquaviva R, Barbagallo I, Li Volti G, Cardile V, et al. Effects of ellagic acid on angiogenic factors in prostate cancer cells. Cancers (Basel). 2013;5(2):726–38. doi:10.3390/cancers5020726.CrossRef

26.

Yousef AI, El-Masry OS, Abdel Mohsen MA. Impact of cellular genetic make-up on colorectal cancer cell lines response to ellagic acid: implications of small interfering RNA. Asian Pac J Cancer Prev. 2016;17(2):743–8.CrossRefPubMed

27.

Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol. 2008;32(2):475–80.PubMed

28.

Viladomiu M, Hontecillas R, Lu P, Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med. 2013;2013:789764. doi:10.1155/2013/789764.CrossRefPubMedPubMedCentral

29.

Padidar S, Farquharson AJ, Williams LM, Kelaiditi E, Hoggard N, Arthur JR, et al. Leptin up-regulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol. 2011;226(8):2123–30. doi:10.1002/jcp.22546.CrossRefPubMed

30.

Ok E, Do GM, Lim Y, Park JE, Park YJ, Kwon O. Pomegranate vinegar attenuates adiposity in obese rats through coordinated control of AMPK signaling in the liver and adipose tissue. Lipids Health Dis. 2013;12:163. doi:10.1186/1476-511X-12-163.CrossRefPubMedPubMedCentral

31.

Fenton JI, Lavigne JA, Perkins SN, Liu H, Chandramouli GV, Shih JH, et al. Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion. Mol Carcinog. 2008;47(1):9–21. doi:10.1002/mc.20357.CrossRefPubMed

32.

Yehuda-Shnaidman E, Nimri L, Tarnovscki T, Kirshtein B, Rudich A, Schwartz B. Secreted human adipose leptin decreases mitochondrial respiration in HCT116 colon cancer cells. PLoS One. 2013;8(9):e74843. doi:10.1371/journal.pone.0074843.CrossRefPubMedPubMedCentral

33.

El-Masry OS, Al-Sakkaf K, Brown BL, Dobson PR. Differential crosstalk between the AMPK and PI3K/Akt pathways in breast cancer cells of differing genotypes: leptin inhibits the effectiveness of AMPK activation. Oncol Rep. 2015;34(4):1675–80. doi:10.3892/or.2015.4198.PubMedPubMedCentral

34.

Pantuck AJ, Pettaway CA, Dreicer R, Corman J, Katz A, Ho A, et al. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18(3):242–8. doi:10.1038/pcan.2015.32.CrossRefPubMed

Title: The anti-oncogenic influence of ellagic acid on colon cancer cells in leptin-enriched microenvironment
Authors: Amany I. Yousef
Omar S. El-Masry
Eman H. Yassin
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5284-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Molecular mechanisms of action of quercetin in cancer: recent advances

Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo

MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN

Arsenite inhibits the function of CD133+ CD13+ liver cancer stem cells by reducing PML and Oct4 protein expression

A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing

Disruption of clock gene expression in human colorectal liver metastases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer